J&J’s stock surrenders early gains as weak sales guidance offsets earnings beat
Johnson & Johnson’s stock reversed gains made early Wednesday immediately after earnings were released, after the medical technology and drug company beat estimates for the fourth quarter, but offered some mixed guidance.
J&J beats in Q4 with in line guidance; so why is its stock falling?
Johnson & Johnson (NYSE:JNJ) fell ~3% in early trading on Wednesday, marking its biggest intraday drop since July 2023, even as the healthcare giant posted better-than-expected financials for Q4 2024 with an in-line earnings outlook for 2025.
J&J Stock Drops Sharply After Earnings Beat
Johnson & Johnson Chief Financial Office Joseph Wolk says its a "little frustrating" to see its stock drop sharply even after reporting an earnings beat on the top and bottom line. The drug maker says a strong dollar will cut into revenue and profit this year.
J&J's Q4 Earnings Beat, Stock Down on Tepid 2025 Sales Guidance
Johnson & Johnson’s JNJ fourth-quarter 2024 earnings came in at $2.04 per share, which beat the Zacks Consensus Estimate of $2.00. Earnings declined 10.9% from the year-ago period. Adjusted earnings exclude intangible amortization expense and special items,
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highligh
J&J beats quarterly sales and profit estimates on cancer drug sales
Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter ...
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
J&J Reports Strong Revenue and Profit but Faces Challenges in 2025
Johnson & Johnson reported better-than-expected quarterly revenue and profit on higher sales of cancer drugs and some medical devices. But shares slipped 3.2% to $143.35 in Wednesday morning trading, ...
J.J. McCarthy returns to on-field training: What it means for Vikings’ QB room
“I’m very excited about where J.J. is at,” Vikings head coach Kevin O’Connell said in an end-of-season press conference.